MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/ML
PFIZER PRIVATE LIMITED
Date of Approval
MYLOTARG is indicated for the treatment of newly-diagnosed, de novo CD33- positive acute myeloid leukemia in adults and pediatric patients 1 month and older, except acute promyelocytic leukemia (APL).
New Drug Indication Approvals